State of the Art of Cancer Therapeutics: Focus on Chronic Lymphocytic Leukemia- Enduring
The rapidly evolving cancer treatment landscape calls for persistent and enhanced education of oncology and hematology clinicians (as well as interventional radiologists, pathologists, pharmacists, and other members of the multidisciplinary care team) who are challenged to stay current with the plethora of new agents and strategies that continue to emerge for a variety of cancer types and subtypes. Oncology practice offers numerous opportunities for personalized, or “precision” medicine, with a burgeoning array of exciting, novel, targeted therapies and immunotherapies that continue to emerge rapidly across a wide variety of tumor types and disease states.
The need for this education is vital, considering recent (and sobering) statistics from the American Cancer Society, estimating a total of 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the United States in 2017. [ACSa] According to multiple sources, the cancer treatment landscape is progressing too quickly for many oncology clinicians—even those who specialize in the management of certain tumor types—to keep pace. Time pressures, stresses, and inefficiencies in the practice of medicine all limit clinicians’ ability to focus on new information. [IOM 2013] This educational initiative that provides a succinct update of the latest and most practical efficacy and safety data for new and emerging cancer treatments is critical to ensure that patients receive high-quality care that will optimize their outcomes.
Community and institution-based medical oncologists, hematologists, surgical oncologists, interventional radiologists, pathologists and other healthcare providers involved in the management of patients with cancer.
- Determine optimal therapy/treatment for patients who have chronic lymphocytic leukemia based on the latest clinical data.
- Integrate and personalize new treatment options for chronic lymphocytic leukemia into clinical practice based on the latest clinical trial data, evidence, and recommendations.
- Outline the various types of cultural diversities (gender, age, race, religion, culture, etc.) that relate to demographics, diagnosis and treatment.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Tanya Siddiqi has indicated that she is a Consultant for AstraZeneca, BeiGene, Ltd., Juno Therapeutics, Inc. and Pharmacyclics, Inc.; On the Speakers Bureau for AstraZeneca, Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc. and Seattle Genetics.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Dr. Siddiqi will be discussing the off label or investigational use of JCAR017, Umbralisib, Ublituximab, Acalabrutinib and Zanubritinib.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
Acknowledgement of Commercial Support: This activity is supported by educational grants from AbbVie, Inc.; Genentech, Inc.; Merck & Co, Inc.; Pharmacyclics, Inc.; and Takeda Oncology.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this State of the Art of Cancer Therapeutics: Focus on Chronic Lymphocytic Leukemia- Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance